Cargando…

Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR

SIMPLE SUMMARY: It is important to understand the impact of viremia on the survival of hepatocellular carcinoma (HCC) in hepatitis C patients. This study aimed to investigate the characteristics and survival between hepatitis C patients with and without viremia at HCC diagnosis. We enrolled 1,389 HC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeh, Ming-Lun, Liang, Po-Cheng, Tsai, Pei-Chien, Wang, Shu-Chi, Leong, Jennifer, Ogawa, Eiichi, Jun, Dae Won, Tseng, Cheng-Hao, Landis, Charles, Tanaka, Yasuhito, Huang, Chung-Feng, Hayashi, Jun, Hsu, Yao-Chun, Huang, Jee-Fu, Dai, Chia-Yen, Chuang, Wan-Long, Nguyen, Mindie H., Yu, Ming-Lung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306695/ https://www.ncbi.nlm.nih.gov/pubmed/34298669 http://dx.doi.org/10.3390/cancers13143455

Ejemplares similares

Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals
por: Lin, Chuan-Pin, et al.
Publicado: (2021)

Effects of Achieving SVR on Clinical Characteristics and Surgical Outcomes in Patients Who Developed Early-Stage HCV-Related Hepatocellular Carcinoma and Received Curative Resection: Preoperative versus Postoperative SVR
por: Hsu, Po-Yao, et al.
Publicado: (2022)

Mac‐2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection
por: Jun, Tomi, et al.
Publicado: (2019)

Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection
por: Liu, Hung-Yin, et al.
Publicado: (2021)

Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study)
por: Huang, Jee-Fu, et al.
Publicado: (2021)

1069. Loss to follow-up does not impact SVR for HCV infection
por: Kottilil, Sita K, et al.
Publicado: (2020)

Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes
por: Huang, Ching-I, et al.
Publicado: (2018)

Therapy as prevention toward HCV elimination in maintenance hemodialysis: a multi-center, prospective cohort study
por: Huang, Chung-Feng, et al.
Publicado: (2023)

A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co–V2 pandemic
por: Huang, Ching-I, et al.
Publicado: (2023)

Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy
por: Huang, Chung-Feng, et al.
Publicado: (2016)

The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan
por: Huang, Ying-Chou, et al.
Publicado: (2021)

Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR
por: Chadha, Nikita, et al.
Publicado: (2022)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
por: Vigón, Lorena, et al.
Publicado: (2019)

Effect of HIV infection-related factors on SVR rate in HCV treatment in HIV-infected patients
por: Kravchenko, Alexey, et al.
Publicado: (2014)

Dose Consideration of Lenvatinib’s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy
por: Lin, Zu-Yau, et al.
Publicado: (2023)

SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China
por: Li, Yanhua, et al.
Publicado: (2017)

HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals
por: Groessl, Erik J., et al.
Publicado: (2017)

Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure
por: Abo-amer, Yousry Esam-Eldin, et al.
Publicado: (2020)

Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy
por: Leuştean, Anca, et al.
Publicado: (2021)

1060. Evaluation of ALT at Sustained Virologic Response (SVR) in Patients with Treated Hepatitis C Virus (HCV) Infection
por: Theppote, Amanda, et al.
Publicado: (2020)

Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR
por: Semmler, Georg, et al.
Publicado: (2021)

Dynamic Changes in Non-Invasive Markers of Liver Fibrosis Are Predictors of Liver Events after SVR in HCV Patients
por: Fernández-Alvarez, Paula, et al.
Publicado: (2023)

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
por: Chang, Te-Sheng, et al.
Publicado: (2023)

Predicting blood pressure from physiological index data using the SVR algorithm
por: Zhang, Bing, et al.
Publicado: (2019)

New treatments for HCV: Perspective from Asia
por: Yu, Ming‐Lung, et al.
Publicado: (2015)

Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index
por: Liu, Ta-Wei, et al.
Publicado: (2020)

Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study
por: Huang, Chung-Feng, et al.
Publicado: (2019)

Peripheral PD-1(+) T Cells Co-expressing Inhibitory Receptors Predict SVR With Ultra Short Duration DAA Therapy in HCV Infection
por: Romani, Sara, et al.
Publicado: (2019)

Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients
por: Batsaikhan, Batbold, et al.
Publicado: (2022)

Itemization difference of patient-reported outcome in patients with chronic liver disease
por: Lin, Ming-Chieh, et al.
Publicado: (2022)

Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Effects of Cirrhosis and Diagnosis Scenario in Metabolic‐Associated Fatty Liver Disease‐Related Hepatocellular Carcinoma
por: Chen, Vincent L., et al.
Publicado: (2020)

Scaling up the in-hospital hepatitis C virus care cascade in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin
por: Thorlund, Kristian, et al.
Publicado: (2014)

Abbott RealTime HBV Assay Is More Sensitive in Detection of Low Viral Load and Little Impacted by Drug Resistant Mutation in Chronic Hepatitis B Patients under Nucleot(s)ide Analogues Therapy
por: Yeh, Ming-Lun, et al.
Publicado: (2014)

The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma
por: Yeh, Ming-Lun, et al.
Publicado: (2017)

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma
por: Lin, Ching-Chih, et al.
Publicado: (2021)

High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis
por: Fu, Zuqiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b55u1t1tvmklqhvpje49ogd6r2